AIDS
Conditions
Keywords
Vaccine, HIV-1, Tat
Brief summary
Tat Oyi vaccination on seropositive patients could help their immune system to recognize and neutralize Tat. The neutralization of extra cellular Tat should help the cellular immune response to eliminate HIV-1 infected cells.
Detailed description
The protocol got a favorable judgment from an ethic committee (CPP SudMed 2) on November 9th, 2012 and was authorized by the French drug agency (ANSM) on January 24th, 2013. It will be proposed to HIV-1 infected volunteers to participate to a phase I/II clinical trial to test the Tat Oyi vaccine. Volunteers will have an undetectable viremia (lower than 40 copies/ml) and a level of CD4 cells higher than 350 /mm3 since at least one year under Anti Retroviral Treatment (ART). It will be a randomized double blinded clinical trial with a placebo. Main Objective: No undesirable events due to vaccination and viremia remaining \< 100 copies/ml after interruption of cART. Secondary objective: An immune response against Tat characterized by the cross recognition of Tat variants representative of the five main HIV-1 clades. Main parameter of evaluation: Plasma viremia. Secondary parameter of evaluation: Detection with ELISA of antibodies able to recognize Tat variants representative of the five main HIV-1 clades.
Interventions
BIOLOGICALTat Oyi
Three injections in the arm
Sponsors
Assistance Publique Hopitaux De Marseille
BIOSANTECH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18 to 64 years old for the pre inclusion visit. * Documented HIV-1 Infection * Preferentially, group A patients from CDC classification but no group C patients. * HIV-1 patients treated with three antiretroviral drugs since 12 months not changed since three months and having an undetectable viremia since 12 months. * HIV-1 Chronic infection defined by a positive HIV-1 ELISA and HIV-1 proteins characterized in a full HIV-1 Western blot. Stable undetectable plasmatic HIV RNA (lower than 40 copies/ml) since 12 months. Lymphocyte CD4 cells higher than 350/mm3 with a NADIR higher than 200/mm3 since 12 months. * Free engagement, fully explained and wrote with the patient signature for the inclusion visit and before any test required for the clinical trial. * Patient affiliated to a social security system. * No vaccination against influenza or other pathogens since three months. * No chemotherapy or treatments with corticosteroid * HIV-1 patients being abstinent former drug users or drug users following substitution training.
Exclusion criteria
* HIV-1 patient protected regarding French law (articles L1121-5, L1121-6, L1121-7, L1121-8 & L1122-2) * No HIV-1 infection * Patient infected with HIV-2 * Patient in HIV-1 primo infection or recently in primo infection * Patient in symptomatic primo infection or CD4 cells lower than 200/mm3 * Women sexually active with no efficient contraception * Pregnant women or brass feeding. * Patient with an opportunistic infection in the CDC group C. * Patient with a cancer and/or under chemotherapy or radiotherapy. * Patient with an evolutive psychiatric pathology * Patient being HBV and/or HCV positive * Patient being ELISA positive for HTLV-1 * Patient being cirrhotic (Child and Pugh level A, B and C) * Patient under criminal investigation * Patients with abnormal blood formulation * Patient participating to another clinical research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal vaccine dose (phase I/II) | Two years | No undesirable events due to vaccination and viremia remaining \< 100 copies/ml after interruption of ART. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Optimal Vaccine Dose (phase I/II) | Two years | An immune response against Tat characterized by the cross recognition of Tat variants representative of the five main HIV-1 clades. |
Countries
France
Outcome results
None listed